Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Retained Earnings (2020 - 2025)

Oncology Institute (TOI) has disclosed Retained Earnings for 6 consecutive years, with -$263.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 33.54% year-over-year to -$263.9 million, compared with a TTM value of -$263.9 million through Sep 2025, down 33.54%, and an annual FY2024 reading of -$210.8 million, down 44.24% over the prior year.
  • Retained Earnings was -$263.9 million for Q3 2025 at Oncology Institute, down from -$247.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$18.4 million in Q1 2021 and bottomed at -$263.9 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$121.8 million, with a median of -$110.0 million recorded in 2023.
  • The sharpest move saw Retained Earnings increased 0.24% in 2022, then tumbled 144.64% in 2023.
  • Year by year, Retained Earnings stood at -$63.2 million in 2021, then increased by 0.24% to -$63.1 million in 2022, then plummeted by 131.68% to -$146.2 million in 2023, then plummeted by 44.24% to -$210.8 million in 2024, then decreased by 25.19% to -$263.9 million in 2025.
  • Business Quant data shows Retained Earnings for TOI at -$263.9 million in Q3 2025, -$247.4 million in Q2 2025, and -$230.4 million in Q1 2025.